Showing results (171-180 of 330) with videos related to

Sort By:
Pageof 33
AMB Express|September 13, 2011
Production of polyhydroxyalkanoates from waste frying oil by Cupriavidus necatorRob Aj Verlinden, David J Hill, Melvin A Kenward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2018
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 StudyScott Gettinger, Leora Horn, David Jackman, et al.
Ecotoxicology and Environmental Safety|June 25, 2026
Divergent evolutionary trajectories and mechanistic insights into arsenite and antimonite adaptation in the bacterium Achromobacter sp. As-55Yanshuang Yu, Chenqiang Lin, Yu Fang, et al.
Environmental Pollution (Barking, Essex : 1987)|December 9, 2024
The paradoxical effects of beneficial bacteria on Solanum lycopersicum under Cd stressMagdalena Noszczyńska, Małgorzata Pawlik, Małgorzata Rudnicka, et al.
JTO Clinical and Research Reports|August 3, 2023
Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective AnalysisIbiayi Dagogo-Jack, Lesli A Kiedrowski, Rebecca S Heist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung CancerJessica J Lin, Elizabeth Kennedy, Lecia V Sequist, et al.
Cancer|December 5, 2018
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studiesMyung-Ju Ahn, Chun-Ming Tsai, Frances A Shepherd, et al.
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2024
Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening EligibilityAlexandra L Potter, Nuo N Xu, Priyanka Senthil, et al.
Pageof 33